everolimus

Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Oral agent improves survival in advanced RCC patientsOnce-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
New Products: FDA approves combination regimen to treat advanced RCCOther products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.
RCC: Two approvals expand options for TKI-refractory patientsFDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
Sunitinib vs. everolimus: PFS, toxicity differ in studyIn a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
Opdivo approved for patients with metastatic renal cell carcinomaFDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Immunotherapy shows survival benefit in advanced RCCAn immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.
Product Preview: Agreement reached for phase III clinical trial of bladder Ca agentIn this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
Breast cancer drug research roundup from ASCOAmong the many poster sessions being presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, are several on the latest trials that are planned to evaluate potential treatment options for breast cancer. These trials include 1 phase 2 study and 3 phase 3 studies.